By: Staff Reporter From: precisiononcologynews.com Columbus, Ohio-based Sermonix Pharmaceuticals said on Wednesday that it is collaborating with Eli Lilly in an upcoming Phase II trial studying Sermonix’s lasofoxifene in combination with Lilly’s CDK 4 and 6 inhibitor abemaciclib (Verzenio) in estrogen receptor-positive, HER2-negative metastatic breast cancer patients who also harbor an ESR1 mutation. The trial, which is expected to start …
-
-
Thanksgiving Day Gratitude as a Breast Cancer Survivor
-
Keeping My Word in the World of Breast Cancer
-
A Hero Moment on Veterans Day from this Breast Cancer Survivor
-
Why This Breast Cancer Survivor Will Enjoy Today for Today
-
Another Little Known Side of Breast Cancer Awareness
